Clinical trials of biosimilars should become more similar
Division of Rheumatology, Department of Medicine
As many more biosimilars are in development, we recommend that clinical trial design be standardised. This standardisation could be agreed upon and overseen by regulatory agencies around the world. The introduction of consistency across clinical trials should increase confidence in these more affordable biopharmaceuticals, both within the healthcare community and among patients.
Rights and Permissions
Citation: Ann Rheum Dis. 2017 Jan;76(1):4-6. doi: 10.1136/annrheumdis-2015-208113. Epub 2016 Aug 25. Link to article on publisher's site
Anti-TNF, Disease Activity, Inflammation, Rheumatoid Arthritis, Treatment
Kay, Jonathan and Isaacs, John D., "Clinical trials of biosimilars should become more similar" (2017). University of Massachusetts Medical School Faculty Publications. 1215.